drugset / Trial / NCT00504933

Efficacy Study for the Symptomatic Treatment of Seasonal Allergic Rhinitis

NCT00504933 ↗

Phase 3 Completed 683 enrolled Faes Farma, S.A.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The objective of the study is to evaluate the efficacy and tolerability of Bilastine 20 mg, compared to Cetirizine and placebo for the treatment of seasonal allergic rhinitis.

Timeline

Start
2005-05
Primary completion
2005-11
Completion
2005-11

Outcome

Met primary endpoint

paper bilastine- and cetirizine-treated groups to a similar and significantly greater extent, compared with placebo (76.5, 72.3 and 100.6, respectively; P<0.001). PMID 19438584 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Bilastine Small molecule 20 mg —
Comparator Cetirizine Other / unclassified 10 mg —